LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Начало・Списък с акции・Altimmune Inc

Altimmune Inc

Затворен

5.34 -1.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.3

Максимум

5.61

Ключови измерители
By Trading Economics
Приходи	3.1M -19M
Продажби	5K
Марж на печалбата	-380,280
Служители	59
EBITDA	4.4M -18M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+139.41% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	236M 585M
Предишно отваряне	7.18
Предишно затваряне	5.34

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

5.365 / 6.0486 Подкрепа & съпротива

Altimmune Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10.12.2025 г., 21:46 ч. UTC

Печалби

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10.12.2025 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise After Fed Rate Cut -- Market Talk

10.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10.12.2025 г., 23:20 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10.12.2025 г., 23:15 ч. UTC

Печалби

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10.12.2025 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10.12.2025 г., 22:45 ч. UTC

Пазарно говорене

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10.12.2025 г., 22:40 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:00 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10.12.2025 г., 21:53 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

10.12.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 21:33 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10.12.2025 г., 21:32 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10.12.2025 г., 21:25 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10.12.2025 г., 21:16 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10.12.2025 г., 21:15 ч. UTC

Печалби

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение с други в отрасъла

Ценова промяна

Altimmune Inc Прогноза

Ценова цел

By TipRanks

139.41% нагоре

12-месечна прогноза

Среден 13 USD 139.41%

Висок 14 USD

Нисък 12 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Altimmune Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Altimmune Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.365 / 6.0486Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.